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Abstract
Background: Noonan syndrome (NS) is an autosomal dominant disorder characterized by specific features
including short stature, distinctive facial dysmorphic features, congenital heart defects, hypertrophic cardiomyopathy,
skeletal anomalies and webbing of the neck. Molecular screening has shown that the majority of individuals
with NS have a mutation in the PTPN11 gene. Noonan syndrome children may show an impaired growth
hormone (GH)/insulin-like growth factor axis. Moreover, recombinant human GH (rhGH) has been shown to
improve growth rate in patients with NS, although data are still limited.
Methods: In the present study, we assessed growth response following GH therapy (0.25 mg/Kg/week) in 5
(2 M and 3 F) GH-deficient NS patients (NSGHD, mean age 8.5 years) and in 5 (2 M and 3 F) idiopathic GH
deficient (IGHD, mean age 8.6 years) patients. We also evaluated the safety of rhGH therapy in NS patients
with GHD.
Results: At the beginning of GH treatment, height and growth rate were statistically lower in NSGHD children
than in IGHD ones. During the first three years of rhGH therapy, NSGHD patients showed a slight improvement in
height (from −2.71 SDS to −2.44 SDS) and growth rate (from −2.42 SDS to −0.23 SDS), although the values were
always significantly lower than in IGHD children. After five years of rhGH treatment, height gain was higher in
IGHD children (mean 28.3 cm) than in NSGHD patients (mean 23.6 cm).
During the first five years of rhGH therapy, regular cardiological and haematological check-ups were performed,
leading to the conclusion that rhGH therapy was safe.
Conclusions: In conclusion, pre-pubertal NS children with GHD slightly increased their height and growth rate
during the first years of GH therapy, although the response to rhGH treatment was significantly lower than
IGHD children. Furthermore, the therapy appeared to be safe since no severe adverse effects were reported,
at least during the first five years. However, a close follow-up of these patients is mandatory, especially to
monitor cardiac function.
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Introduction
Noonan syndrome (NS) is a disorder first reported by
the paediatric cardiologist Jaqueline Noonan in 1963 [1]
and described in detail a few years later by the same au-
thor [2] and then by other groups [3]. It is an autosomal
dominant disorder, affecting 1 in 1,000–2,500 live births
with no sex predominance, and is the most common
syndromal cause of congenital heart disease, except for
Down’s syndrome.
Noonan syndrome is characterized by short stature,
distinctive facial dysmorphic features including hyper-
telorism, down-slanting palpebral fissures and low-set
posteriorly rotated ears, congenital heart defects, hyper-
trophic cardiomyopathy, skeletal anomalies and web-
bing of the neck. Other relative common features are
bleeding diathesis, ectodermal anomalies, lymphatic
dysplasia, cryptorchidism and cognitive deficits [4–7].
The clinical features become more evident with age [5]
and the diagnosis is principally clinical. At present, genetic
testing is available to confirm or make the diagnosis. In
fact, NS is caused by mutations in genes that encode pro-
teins of the RAS-MAPK signal transduction pathway [8].
Molecular screening has shown that the majority of indi-
viduals with a diagnosis of NS have a mutation in the
PTPN11 gene (30–60 %) that encodes for the protein
tyrosine phosphatase SHP2 [8]. Other mutations have
been described in KRAS, RAF1, SOS1, NRAS and SHOC2
genes. However, a failure to identify a mutation does not
exclude the diagnosis of NS [9, 10].
Growth in NS has been a subject of interest since its
first description in 1963 [1]. Short stature is reported
in 50–70 % of patients with NS and the majority of af-
fected patients have height below the third percentile
[2–7, 11, 12]. Mean adult stature ranges from 145–
162.5 cm for men and 135–151 cm for women [11].
Birth weight and length are typically normal, but sub-
sequent delayed growth rate affects height, weight and
bone development. After the first months of life there
is a progressive deceleration of linear growth. Bone
age after the age of 5 years is generally retarded (about
2 years). Puberty is often delayed and catch-up growth
does not occur.
Children with NS are not usually growth hormone defi-
cient (GHD), but may show some abnormalities in the GH/
insulin-like growth factor (IGF) axis [13, 14]. Recombinant
human GH (rhGH) has been shown to improve growth
rate in NS patients as in patients with Turner’s syndrome
[15, 16], but data are yet still limited. Most of the evidence
of rhGH effects on NS children growth comes from obser-
vational studies in small numbers of patients and without
randomization or control groups (Table 1).
In the present study, we assessed growth response fol-
lowing GH therapy in GH-deficient NS patients (NSGHD)
and compared it with idiopathic GH deficient (IGHD) sex
Table 1 Published data from studies of GH treatment in Noonan patients
Reference No. patients
(M/F)






Height SDS at last
observation#
Ahmed et al. 1991 [25] 6 (3/3) From −3.5 to −2.3 0.18 1 -
Thomas et al. 1993 [31] 5 (4/1) From −4.2 to −2.2 0.35 2.9 From −3.3 to −1.6
Municchi et al. 1995 [32] 4 (0/1) From −1.9 to 0.2* 0.17 3 From −0.9 to 0.9*
Cotterill et al. 1996 [33] 30 (19/11) −3.01 ± 0.1 0.33 1 −2.36 ± 0.1
de Schepper et al. 1997 [15] 23 (18/5) −2.28 ± 0.68 0.35 1 −1.78 ± 0.76
Soliman et al. 1998 [34] 12 (3/9) −2.2 ± 0.6 0.28 1 1.45 ± 0.3
MacFarlane et al. 2001 [35] 23 (16/7) −2.7 ± 0.4 0.33 3 −1.9 ± 0.9
Ogawa et al. 2004 [36] 15 (8/6) −2.8 ± 0.7 0.17 2 −2.2 ± 0.5
Ferreira et al. 2005 [22] 14 (10/4) −3.5 ± 1.0 (PTPN11 mutation) 0.29 3 0.76 ± 0.41 (PTPN11 mutation)
−3.4 ± 1.0 (no PTPN11 mutation) 1.74 ± 0.10 (no PTPN11 mutation)
Binder et al. 2005 [37] 29 (19/10) −3.5 ± 1.0 (PTPN11 mutation) 0.30 1 0.66 ± 0.21 (PTPN11 mutation)$
−3.4 ± 1.0 (no PTPN11 mutation) 1.26 ± 0.36 (no PTPN11 mutation)$
Osio et al. 2005 [38] 25 (12/13) −2.9 ± 0.4 0.23-0.46 1-9 −1.2 ± 1.0
Limal et al. 2006 [23] 35 (19/16) −3.1 ± 0.9 (PTPN11 mutation) 0.30-0.46 2 −3.1 ± 1.4 (PTPN11 mutation)
−2.4 ± 0.8 (no PTPN11 mutation) −2.0 ± 0.9 (no PTPN11 mutation)
Noordam et al. 2008 [21] 29 (21/8) From −4.1 to −1.8 0.35 3-10.3 From −3.0 to −0.3
Choi et al. 2012 [24] 28 (14/4) −2.8 ± 0.9 0.46 1 −2.0 ± 0.9
#Mean ± standard deviation or range
*Noonan reference [39]
$Change in height SDS
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and age-matched patients. We also evaluated the safety of
rhGH therapy in NS patients with GHD.
Patients and methods
Patients
We studied 10 pre-pubertal children, 5 NS patients (2
males and 3 females) with GHD and 5 patients (2 males
and 3 females) with IGHD. The diagnosis of GHD was
established when GH response to at least two pharmaco-
logical stimuli was lower than 10 ng/ml in the presence
of short stature, reduced growth velocity and delayed
bone age [17]. None of the patients had diabetes insipi-
dus, chromosomal abnormalities, dysmorphic syndromes
or acquired GHD, after careful clinical evaluation. All
subjects showed normal thyroid and adrenal function.
Magnetic resonance imaging of the hypothalamus and
pituitary region was performed in all patients.
In NS children, the mean chronological age was 8.5 years
(standard deviation, SD: 3.1), height was −2.70 standard de-
viation score (SDS) (SD: 0.42), growth velocity was −2.24
SDS (SD: 3.80) and body mass index (BMI) was −1.54
SDS (SD: 0.31). In patients with IGHD, chronological
age was 8.6 years (SD: 4.0), height was −1.82 SDS (SD:
0.71), growth velocity was −1.08 SDS (SD: 1.44) and
BMI was −0.99 SDS (SD: 0.82).
The diagnosis of NS was clinically established by phy-
sicians experienced with NS on the basis of the Van der
Burgt criteria [6, 7]. Genetic analysis was also performed
and showed different mutations. In 4 out of 5 patients
we found four different PTPN11 mutations affecting dif-
ferent exons of the gene. The other patient showed a
mutation in the KRAS gene. Every NS child had a
proper cardiological, endocrinological (thyroid and ad-
renal) and oral glucose tolerance test evaluation, before
starting rhGH therapy. In our NS patients no major car-
diological criteria were detected.
All IGHD children showed normal birth weight and
length for gestational age. Anthropometric data were
measured by experienced physicians both at the time of
GHD diagnosis and at regular follow-up intervals using
the Tanner standard [18].
According to the recommendations for the use of
rhGH in children, rhGH therapy was administered at
the weekly dose of 0.25 mg/kg subcutaneously subdi-
vided in 6 daily doses in the evening in both the
NSGHD and IGHD children.
Ethics, consent and permissions
Informed consent regarding diagnostic and therapeutic
approaches was obtained from parents of all subjects.
Statistical analysis
The results for quantitative variables are expressed as mean
values and SD (the Shapiro-Wilk test was used to test the
normal distribution of variables). Linear regression models
for repeated measures were used to analyse differences
over time and among different patient groups. Two-
sided p values <0.05 were considered statistically sig-
nificant. Stata 13.0 (StataCorp 2013, College Station,
Texas) was used for all computations.
Results
Children affected by NS and GHD and children with only
GHD had comparable chronological age and BMI at the
time of endocrinological evaluation. On the contrary, they
differed in height and growth rate, which were statistically
lower in NSGHD children than in IGHD ones.
During the years of therapy, NSGHD patients showed a
slight improvement in height, from a mean value of −2.71
SDS to −2.44 SDS (Fig. 1). This increase was evident dur-
ing the first three years of treatment, with a statistical sig-
nificant increase in height during the second (p = 0.026)
and third year (p = 0.022) of treatment compared to basal
values; in the last two years height SDS values appeared to
be constant. On the contrary, IGHD patients showed a
good response to rhGH therapy during the follow-up, with
a statistically significant increase from −1.82 SDS to −0.59
SDS. Therefore, the patterns of height SDS values
were significantly different between the two groups
during the first five years of rhGH treatment. The dif-
ferent height patterns of each NSGHD child paired
with a sex and age-matched IGHD control are shown
in the panels of Fig. 2. Each NSGHD patient showed
a significantly lower height than the corresponding
sex and age-matched IGHD one.
The height gain after five years of rhGH treatment
was higher in IGHD children (28.3 cm, SD: 4.7; 1.13
Fig. 1 Height before and during the first five years of rhGH
replacement therapy in NSGHD (closed square) and IGHD patients
(closed triangle). Data are represented as mean and SD. §p < 0.005
NSGHD versus IGHD at the corresponding time. *p < 0.05 in NSGHD
children versus time = 0
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SDS, SD: 0.39) than in NSGHD patients (23.6 cm,
SD: 2.2; 0.29 SDS, SD: 0.28), although the difference
was not statistically significant (p = 0.061).
Growth rate was also different between the two
groups at baseline and during the five-year follow-up.
This difference is not due to the pubertal develop-
ment of patients, since during the five years of
follow-up four patients out of five entered puberty in
both groups. During the first year of therapy, growth
rate increased in a similar way in NSGHD and IGHD
subjects (from a mean value of −2.42 SDS to −0.23
SDS and from −1.09 SDS to 1.78 SDS, respectively)
(Fig. 3). In particular, in NSGHD patients growth rate
significantly increased during the second year of treat-
ment (p = 0.032). Then, growth rate values remained
quite constant in both groups, being always higher in
IGHD children.
Body mass index values did not significantly change
during the first five years of rhGH therapy in both groups
of subjects, although the values were always higher in
IGHD than in NSGHD children (data not shown).
During the first five years of rhGH therapy, regular
cardiological and haematological check-ups were per-
formed; the results suggest that rhGH therapy is safe in
this kind of patient.
Discussion
In this study we evaluated the growth-promoting efficacy
of rhGH therapy in children with NSGHD comparing
them with idiopathic GHD children only, during the first
five years of therapy. Both groups of patients were
treated with the dose of GH usually used for IGHD
























Fig. 3 Growth velocity before and during the first five years of
rhGH replacement therapy in NSGHD and IGHD patients. Data are
represented as mean and SD. §p < 0.005 NSGHD versus IGHD at the
corresponding time. *p < 0.05 in NSGHD children versus basal time = 0
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children. It is interesting to underline that this dose is
lower than the dose used by many authors to treat NS
patients without GHD.
Short stature is a typical feature of children with NS.
The cause of short stature is the affection of proteins
of the RAS-MAPK pathway. Furthermore, a genotype-
phenotype correlation has also been hypothesized. In
fact, short stature is most prevalent in patients with
mutations in the PTPN11 gene, probably due to the
fact that SHP2 is involved in GH receptor signalling.
Since 2007, the use of rhGH in patients with NS has
been approved by the U.S. Food and Drug Administration
(FDA) at a high dose (33–66 μg/kg/day) [19]. The re-
ported studies (Table 1), despite the small sample size of
cohorts and the short time of treatment, indicate that
short-term rhGH therapy increases mean height SDS in
short children with Noonan syndrome and the height gain
was reported to be 0.6-2.0 SDS, which is equivalent to 4–
13 cm [20]. Noordam et al. published data which con-
cluded that rhGH improves adult height (mean gain in
height-SDS of +1.3) in Noonan syndrome with and with-
out the PTPN11 mutation [21]. In some studies, gene mu-
tations in Noonan patients seem also to influence the
response to GH therapy. In fact, decreased IGF-I levels
and reduced response to GH treatment in NS children
with PTPN11 mutations have been reported, suggesting a
mild form of GH resistance [22, 23]. On the contrary, in
other studies no significant differences in height SDS,
height velocity and serum IGF-I level in response to rhGH
treatment were found between children with or without
PTPN11 mutations [21, 24].
Unfortunately, in our present study we were not able
to conclude whether PTPN11 mutations could affect
height or response to rhGH therapy, since four out of
five patients present mutations in this gene.
In Italy, treating Noonan children with rhGH is not
allowed unless a condition of GH deficiency is found, as
in our patients. However, disturbances in GH secretion
(low nocturnal levels of GH or an unusual pulsatility of
GH levels) or action seem to be involved in the patho-
genesis of NS [25, 26].
Our NSGHD patients showed only a slight increase in
height and growth rate during rhGH therapy and this in-
crease was more evident during the second and third
year of treatment. The response was significantly lower
than that shown by IGHD only age- and sex-matched
children. Furthermore, we administered the same doses
of GH that are used in idiopathic GHD children, which
are lower than those used in other studies with Noonan
GH sufficient children. This different response to GH
therapy is not due to the pubertal development of pa-
tients, since during the five years of follow-up four out
of five patients entered puberty in both groups. How-
ever, since puberty in NS children is typically delayed,
early initiation of rhGH therapy and long pre-pubertal
duration should result in improved height at pubertal
onset and in a less affected final height [27].
According to other studies, we found that BMI is not
affected by rhGH treatment. However, it has been shown
that favourable changes in fat mass and body compos-
ition are achievable during rhGH treatment in NS pa-
tients [28].
Noonan syndrome is generally associated with cardiac
defects, such as mild or severe hypertrophic cardiomio-
pathy, which has raised concerns related to the anabolic
effects of rhGH and the possible progression of ventricu-
lar hypertrophy. However, earlier reports have shown
that GH treatment is not associated with cardiac impair-
ment in this group of patients [29].
In our NS patients, who did not show any cardiac de-
fect at the beginning of the therapy, we reported no se-
vere adverse events during GH-treatment, in particular
no cardiac adverse events (i.e. hypertrophic cardiomyop-
athy). However, we suggest that, before starting rhGH
treatment, every child with NSGHD should undergo car-
diological evaluation with echocardiography and then a
regular cardiological follow-up during rhGH therapy.
Furthermore, patients with NS are predisposed to have
a higher risk for leukaemia and certain solid tumours, es-
pecially if they carry PTPN11 mutations [30]. Therefore, a
close follow-up of these subjects is necessary in order to
determine whether rhGH increases the risk of neoplasia.
In conclusion, pre-pubertal NS children with GHD
slightly increase their height and growth rate during the
first five years of GH therapy, although the response to
GH treatment is significantly lower than IGHD children.
Furthermore, the therapy appears to be safe since no se-
vere adverse effects were reported, at least during the first
five years. However, a close follow-up of these patients is
mandatory, especially for monitoring cardiac function,
haematological abnormalities or bleeding disorders.
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